Pre-clinical studies provide evidence that blockade of PD-1 and CTLA-4 could reverse immune dysfunction and improve survival in sepsis, and three recently published phase-1 studies showed that PD-1 and PD-L1 antibody administered to patients with severe sepsis could restore immune cell function in septic patients with low lymphocyte count [9, 10, 15]. The gene discussed is CD274; the disease is Sepsis.